Many of the top selling drugs worldwide are biologics and many companies are seeking to produce biosimilars to compete in these lucrative markets. Activity relating to biosimilars is intensifying in the US following the introduction of the BPCIA and continues in Europe since the first biosimilars were authorised in 2006. Successfully bringing a biosimilar to market raises different challenges to small molecule generics and there are differences in the approach in the US and Europe.
Taylor Wessing and Willkie Farr & Gallagher are hosting a series of three webinars covering various aspects of market access for biosimilars.
In this first webinar 'Biosimilars - an overview of the route to market in the US and Europe' we discussed: